The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Open accessAbstract
Background Elevated lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS). Oxidized phospholipids (OxPL) are key mediators of calcification in valvular cells and are carried by Lp(a).Objectives This study sought to determine whether Lp(a) and OxPL are associated with hemodynamic progression of AS and AS-related events.Methods OxPL on apolipoprotein B-100 (OxPL-apoB), which reflects the biological activity of Lp(a), and Lp(a) levels were measured in 220 patients with mild-to-moderate AS. The primary endpoint was the progression rate of AS, measured by the annualized increase in peak aortic jet velocity in m/s/year by Doppler echocardiography; the secondary endpoint was need for aortic valve replacement and cardiac death during 3.5 ± 1.2 years of follow-up.Results AS progression was faster in patients in the top tertiles of Lp(a) (peak aortic jet velocity: +0.26 ± 0.26 vs. +0.17 ± 0.21 m/s/year; p = 0.005) and OxPL-apoB (+0.26 ± 0.26 m/s/year vs. +0.17 ± 0.21 m/s/year; p = 0.01). After multivariable adjustment, elevated Lp(a) or OxPL-apoB levels remained independent predictors of faster AS progression. After adjustment for age, sex, and baseline AS severity, patients in the top tertile of Lp(a) or OxPL-apoB had increased risk of aortic valve replacement and cardiac death.Conclusions Elevated Lp(a) and OxPL-apoB levels are associated with faster AS progression and need for aortic valve replacement. These findings support the hypothesis that Lp(a) mediates AS progression through its associated OxPL and provide a rationale for randomized trials of Lp(a)-lowering and OxPL-apoB-lowering therapies in AS. (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin [ASTRONOMER]; NCT00800800).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical factors associated with faster stenosis progression include older age, female sex, severity of the stenosis and degree of aortic valve calcification at diagnosis, smoking, hypertension, obesity, metabolic syndrome, secondary hyperparathyroidism, renal failure elevated circulating levels of Lp(a), and increased activity of Lp-PLA2 (also called lipoprotein–associated phospholipase A2)51”
From Calcific aortic stenosis (2016) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the presence of elevated plasma Lp(a) (>50 mg per dL; the upper normal limit is <30 mg per dL)) is associated with a twofold faster stenosis progression51.”
From Calcific aortic stenosis (2016) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, Capoulade and colleagues showed that circulating Lp(a) and Ox-PL levels were independently associated with faster progression of calcific AS51.”
From Calcific aortic stenosis (2016) · cites this paper as [51]
In the citing paper
“prior studies have linked ApoB to the onset and accelerated progression of CAVD [38,39].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,487
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Guidelines on the management of valvular heart disease
Vahanian, A. S., Baumgartner, H., Bax, J. J., Butchart, E., Dion, R., Filippatos, G. S., Flachskampf, F., Hall, R., Iung, B., Kasprzak, J. D., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl428 · Cited by 3,579
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000029 · Cited by 2,566
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O'Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.537 · Cited by 1,642
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Flagged first, then by citations
Research works printed but not linked: 1
- Tsimikas, 2015, Antisense therapy targeting apolipoprotein (a) reduces plasma lipoprotein(a) Levels, Lancet
Cited by
Sorted by citations
Items 401–417 of 417
Chemello, K. (2022) · theses.fr (ABES) · doi:10.70675/6f647f12za09bz494fzae02z9be71ebf2915
Gómez-Barrado, J. J., Ramos, Y. P., Romero-Castro, M. J., Beltran-Moreno, M., & Gómez-Turégano, P. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.05.221
The Genetic Stamp of Lipoprotein(a): Moving Beyond LDL for Cardiovascular Risk Estimation
Solimene, A., Luisi, E., Morello, M., Titolo, G., Serpico, C., Granata, M., Acampora, B., Bernazeaut, J., Loffredo, F. S., Golino, P., et al. (2026) · Targets · doi:10.3390/targets4030023
Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved
Polo-Barranco, A., Rebolledo-Maldonado, C., Rodelo-Barrios, D., Solano-Ropero, J., Rada-Obeso, V., Lavalle-Jiménez, C. M., Blanchar-Martínez, V., Beltran-Sánchez, C., Maza-Arnedo, A., Herrera-Calvo, T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156639
The role of lipoprotein (a) in premature cardiovascular disease: primed for prevention
Safarova, M. S., Sperling, L. S., Mehta, A., Bhatia, H. S., & Rodríguez, F. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag313
Clodi, N., Schörghofer, N., Knapitsch, C., Scharinger, B., Gressl, M., Hecke, G., Lichtenauer, M., Brandt, M., Kremser, I., Reiter, C., et al. (2026) · Medical Sciences · doi:10.3390/medsci14040484
Syed, A. B., Michalak, S., Potulapati, I., Vignarajah, A., & Shah, G. V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176640
Echeverria-Ortegon, E., Torres-Chavez, M. C., TEJEDA, A. P. T., Caballero, P., & Pastor-Cervantes, J. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.003
Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention
Bene-Alhasan, Y. O., Nambi, V., Abushamat, L. A., & Ballantyne, C. M. (2026) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1836
Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions
Sabouret, P. F., Giamundo, D. M., Popiołek-Kalisz, J., Spadafora, L., Bernardi, M., Asher, E., Mamas, M. A., Atar, D., & Andò, G. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm55004
Novel pharmacological targets for the treatment of aortic stenosis
Anchouche, K., Small, A. M., & Thanassoulis, G. (2026) · European Heart Journal - Valvular and Structural Heart Disease · doi:10.1093/ehjvshd/xwag069
Trimaille, A., & Capoulade, R. (2026) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2026.10.005
Self-citationZhang, X., Si, Y., Liao, L., & Wu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1906690
Li, W., Shuang, S. Y., An, Y. B., Xu, Y., Hao, W., Xu, X. S., Lian, P. X., & Feng, M. Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1963618
Liu, F., Zeng, Z., 钱, 之., Li, W., Huang, Y., & Liu, Z. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1997440
Metadata
- Authors
- Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., Witztum, J. L., Arsenault, B. J., Després, J.-P., Pibarot, P., & Tsimikas, S.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Ottawa Heart Institute (CA)
- University of California San Diego (US)
- St. Boniface Hospital (CA)
- McMaster University (CA)
- Corresponding author
- Tsimikas, Sotirios
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 66
- Issue
- 11
- Pages
- 1236-1246
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1609565130
- Cited by
- 417
- References
- 45
- Citations by year
- 2026: 26 · 2025: 49 · 2024: 37 · 2023: 37 · 2022: 52 · 2021: 30 · 2020: 40 · 2019: 47 · 2018: 26 · 2017: 38 · 2016: 32 · 2015: 3
- FWCI
- 24.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Corpus Université Laval (Université Laval) (submittedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- National Institutes of Health (HL055798, HL088093)
- University of California, San Diego
- Pfizer Canada
- Eli Lilly Canada
- Canadian Institutes of Health Research (MOP# 114997, MOP-245048, 114997, 245048)
- National Heart, Lung, and Blood Institute (HL-055798, HL093767, R01HL093767, HL119828, P01HL055798, R01HL119828, HL-088093, P01HL088093)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- aortic stenosis, calcific aortic stenosis, lipoprotein(a), oxidized phospholipids, apolipoprotein B-100, disease progression, aortic jet velocity, aortic valve replacement, cardiovascular mortality, valve calcification, Lp(a)-lowering therapy
- MeSH terms
- Adult, Aged, Aortic Valve, Aortic Valve Stenosis, Calcinosis, Death, Female, Humans, Male, Middle Aged, Oxidation-Reduction, Phospholipids, Ultrasonography, Biomarkers, Lipoprotein(a), Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
